Mar 24, 2025 8:00 am EDT Axogen Announces Appointment of Rick Ditto as Vice President, Global Health Economics, Reimbursement & Policy, and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Feb 11, 2025 4:58 pm EST Axogen, Inc. to report 2024 fourth quarter and full year financial results on February 25, 2025
Feb 3, 2025 8:00 am EST Axogen Announces Appointment of Jesse Bishop as Vice President of Regulatory Affairs and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 10, 2025 5:00 pm EST Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Jan 10, 2025 8:00 am EST Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
Nov 7, 2024 7:00 am EST Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
Oct 24, 2024 7:00 am EDT Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
Sep 6, 2024 7:00 am EDT Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
